Skip to main content
OpenTrials

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,075 public trials 581 recruiting studies
Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Completed

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

NCT04042376

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • The First Hospital of Jilin University Changchun, China
  • First affiliated Hospital of Zhejiang University Hangzhou, China
  • Institute of Hematology and Blood Diseases Hospital Tianjin, China
  • Wuhan Union Hospital Wuhan, China
View Trial Details
Completed

Short Course Daratumumab in Patients With Multiple Myeloma

NCT03490344

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Memoral Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memoral Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
View Trial Details
Completed

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

NCT04062448

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Kameda Medical Center Chiba, Japan
  • National Cancer Center Hospital Chūōku, Japan
  • National Hospital Organization Kumamoto Medical Center Kumamoto, Japan
  • Matsuyama Red Cross Hospital Matsuyama, Japan
View Trial Details
Completed

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

NCT03941860

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • CHI Saint Vincent Cancer Center Hot Springs Hot Springs, Arkansas, United States
  • Mission Hope Medical Oncology - Arroyo Grande Arroyo Grande, California, United States
  • Pacific Central Coast Health Center-San Luis Obispo San Luis Obispo, California, United States
View all 222 locations
View Trial Details
Completed

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

NCT02519452

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Atlanta, Georgia, United States
  • New York, United States
  • Charlotte, North Carolina, United States
  • Philadelphia, Pennsylvania, United States
View Trial Details
Completed

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT03361748

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Local Institution - 108 San Francisco, California, United States
  • University of California - San Francisco San Francisco, California, United States
  • Emory University Atlanta, Georgia, United States
  • Local Institution - 103 Atlanta, Georgia, United States
View all 48 locations
View Trial Details
Completed

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

NCT03158688

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Lynn Cancer Center Boca Raton Regional Hospital, Lynn Cancer Institute Boca Raton, Florida, United States
  • Emory University Winship Cancer Institute Atlanta, Georgia, United States
  • University of Chicago Medical Center - Multiple Myeloma Research Consortium Chicago, Illinois, United States
  • Fort Wayne Medical Oncology and Hematology Fort Wayne, Indiana, United States
View all 113 locations
View Trial Details

Related conditions